Shire PLC (NASDAQ:SHPG) – Analysts at SunTrust Banks decreased their FY2019 earnings per share (EPS) estimates for Shire PLC in a report issued on Monday. SunTrust Banks analyst J. Boris now expects that the biopharmaceutical company will post earnings of $18.59 per share for the year, down from their previous estimate of $20.24. SunTrust Banks also issued estimates for Shire PLC’s FY2020 earnings at $21.47 EPS and FY2021 earnings at $24.54 EPS.
Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.64 by $0.17. Shire PLC had a return on equity of 14.41% and a net margin of 10.95%. The company had revenue of $3.70 billion for the quarter. During the same quarter in the prior year, the firm earned $3.17 earnings per share. Shire PLC’s revenue for the quarter was up 7.1% compared to the same quarter last year.
Several other equities research analysts also recently issued reports on the company. FBR & Co restated a “buy” rating and set a $201.00 price objective on shares of Shire PLC in a report on Monday, October 30th. Cowen and Company set a $225.00 price objective on Shire PLC and gave the stock a “buy” rating in a report on Sunday, October 29th. Cantor Fitzgerald restated a “buy” rating and set a $222.00 price objective on shares of Shire PLC in a report on Friday, October 27th. Zacks Investment Research upgraded Shire PLC from a “sell” rating to a “hold” rating in a report on Friday, October 27th. Finally, Piper Jaffray Companies restated a “hold” rating and set a $160.00 price objective on shares of Shire PLC in a report on Friday, October 27th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $211.00.
Shire PLC (NASDAQ SHPG) traded up $0.29 during mid-day trading on Thursday, reaching $140.36. The company’s stock had a trading volume of 699,839 shares, compared to its average volume of 1,137,305. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55. Shire PLC has a 52 week low of $137.80 and a 52 week high of $192.15. The stock has a market cap of $42,240.00, a P/E ratio of 9.72, a PEG ratio of 0.78 and a beta of 1.60.
A number of large investors have recently added to or reduced their stakes in the stock. Third Point LLC acquired a new position in Shire PLC during the 3rd quarter valued at approximately $183,768,000. Amundi Pioneer Asset Management Inc. boosted its position in Shire PLC by 26.1% during the 3rd quarter. Amundi Pioneer Asset Management Inc. now owns 85,399 shares of the biopharmaceutical company’s stock valued at $13,078,000 after purchasing an additional 17,700 shares during the period. FNY Partners Fund LP boosted its position in Shire PLC by 168.5% during the 3rd quarter. FNY Partners Fund LP now owns 106,246 shares of the biopharmaceutical company’s stock valued at $16,270,000 after purchasing an additional 66,670 shares during the period. ETRADE Capital Management LLC boosted its position in Shire PLC by 8.5% during the 3rd quarter. ETRADE Capital Management LLC now owns 6,746 shares of the biopharmaceutical company’s stock valued at $1,033,000 after purchasing an additional 528 shares during the period. Finally, GMT Capital Corp acquired a new position in Shire PLC during the 3rd quarter valued at approximately $15,714,000. Institutional investors and hedge funds own 19.24% of the company’s stock.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.